SERB Acquires Y-mAbs: Rare Oncology Expansion
SERB Pharmaceuticals acquires Y-mAbs for $412M, gaining DANYELZA, an FDA-approved treatment for high-risk neuroblastoma, enhancing rare oncology portfolio.
/ 41 items
#Healthcare↓
Pfizer's Profit Outlook Rises Amidst Strong Q2 Performance
Pfizer boosts its 2025 profit forecast due to ongoing cost reductions and strong second-quarter sales driven by top-performing drugs.
Vertex Faces Pain Drug Setbacks Amidst Q2 Earnings Beat
Vertex Pharmaceuticals' stock fell after its pain drug VX-993 failed a trial. Despite this, Q2 earnings exceeded estimates, driven by cystic fibrosis drugs. Journavx also faces FDA limitations.
Hims & Hers Q2: Profit Soars, Revenue Miss Sparks Share Drop
Hims & Hers' Q2 profit surged to $42.5M, fueled by 31% subscriber growth (2.4M total). Revenue of $544.8M missed estimates, impacted by wholesale weakness, causing shares to fall. Full-year guidance maintained.
Trump Admin Eyes Major GLP-1 Weight Loss Drug Coverage
The Trump administration is considering a five-year pilot program for Medicare & Medicaid to cover costly GLP-1 weight-loss drugs like Wegovy & Zepbound for millions, a significant policy shift.
VYNE Therapeutics' Vitiligo Trial Fails, Shares Plummet 74%
VYNE Therapeutics announced its Phase 2b trial for Repibresib gel in non-segmental vitiligo missed primary and key secondary endpoints, leading to trial termination and a share slump.